Journal article

Immunotherapy in breast cancer: the subtype story

Stephen J Luen, Sherene Loi

CANCER FORUM | AUSTRALIAN CANCER SOC INC | Published : 2016

Abstract

Great hopes have been accorded to the potential of immunotherapy to exploit host anti-Tumour immunity and deliver improved survival outcomes. Impressive results in cancers known to be immunogenic have led to a plethora of immunotherapy trials in several cancer types, including breast cancer. Descriptions of tumour-infiltrating lymphocytes in early breast cancer have unravelled the landscape of immunogenicity across the breast cancer subtypes, and provide rationale for investigation into immunotherapeutic approaches. Subsequently, numerous clinical trials have been launched, predominantly with checkpoint blockade. While triple negative and HER2-positive breast cancers appear to be more immuno..

View full abstract